BioSpace News Archive

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced that positive results from a Phase 2 trial of MN-166 in alcohol use disorder were published in Nature’s Translational Psychiatry.

Biotage is pleased to announce the launch of Biotage® PhyPrep, a new automated platform for plasmid DNA purification that releases laboratory staff from the tedium of repetitive, manual labor - and takes full advantage of the PhyTip® columns’ dual flow chromatography technology, to yield supercoiled, endotoxin-free, transfection-grade plasmid DNA.

Aerie Pharmaceuticals, Inc. announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Raymond James Human Health Innovation Conference on Tuesday, June 22, 2021 at 1:20 p.m. Eastern Time.

Enochian BioSciences, Inc. announced that the company has acquired an exclusive license for an innovative technology to potentially treat and prevent all variants of coronavirus, including the cause of COVID-19, as well as influenza.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced presentation of the positive Phase 2 safety and efficacy data for oral opaganib [1] in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum 2021.

Diffusion Pharmaceuticals Inc. today announced that CEO Robert Cobuzzi, Jr., Ph.D., will present via webcast at the Life Sciences Investor Forum being held on June 24, 2021.

GenScript Biotech Corporation announced today that the U.S. Patent and Trade Office has issued a notice of allowance for the patent application for a novel Surrogate Virus Neutralization Technology.

CytomX Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, announced that results from its Phase 1 first-in-human study of CX-2029 in patients with advanced solid tumors were published online in the peer-reviewed journal Clinical Cancer Research.

Intercept Pharmaceuticals, Inc. announced that multiple abstracts regarding the treatment of primary biliary cholangitis and nonalcoholic steatohepatitis with obeticholic acid will be presented at the Digital International Liver Congress™ 2021, the 56th Annual Meeting of the European Association for the Study of the Liver, to be held virtually from June 23 to June 26, 2021.

T2 Biosystems, Inc. today announced the Company’s participation in three virtual conferences this summer.